Navigation Links
Medivation to Present at 8th Annual Needham Life Sciences Conference
Date:6/4/2009

SAN FRANCISCO, June 4 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the 8th Annual Needham Life Sciences Conference on Thursday, June 11, at 10:30 a.m. Eastern Time at the New York Palace Hotel.

Dr. Hung will provide an overview of Medivation and its clinical development programs for Dimebon for Alzheimer's and Huntington's diseases and MDV3100 for prostate cancer.

A live audio webcast of the corporate presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at http://www.medivation.com. A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program that includes several Phase 3 trials assessing the efficacy and safety of Dimebon taken alone or in combination with other Alzheimer's medication in patients with mild, moderate or severe Alzheimer's disease. Further development of Dimebon in patients with Huntington's disease is also planned. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at http://www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Medivation Announces Offering of 2,750,000 Shares of Common Stock
2. Medivation Announces Upcoming Presentation of New MDV3100 Data in Patients With Advanced Prostate Cancer at 45th American Society of Clinical Oncology Annual Meeting
3. Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference
4. Medivation Reports First Quarter 2009 Financial Results and Provides Corporate Update
5. Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
6. Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009
7. Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
8. Medivation Announces Participation in Upcoming Conferences
9. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
10. Medivation Announces Participation in Upcoming Conferences
11. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2016)... ... 10, 2016 , ... When faced with having to use a toilet away ... to her body, and contamination of children when they use public toilets. This inspired ... that many people face. , The patent-pending SANI-POCKET enables a person to use a ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... planning assistance from offices in Pasco and Richland, is initiating a charity drive ... serious injuries resulting from a recent automobile collision. , On October 29th ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... miniature, folded, pharmaceutical inserts and outserts. As a means of expanding capabilities ... addition will enable Flottman to individually code professional inserts (PIs) and patient package ...
(Date:12/9/2016)... Heights, NY (PRWEB) , ... December 09, 2016 , ... ... Alcoholism and Drug Dependence, Inc. (NCADD) is recommending the film Whispering Spirits ... states and the District of Columbia as an education tool in the war against ...
(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, Va., wanted to ... types of amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves accessibility. ... and could be set up in a matter of minutes, or even seconds. The ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016  Nevro Corp. (NYSE: ... is providing innovative evidence-based solutions for the treatment of ... BSX ) has filed a lawsuit for patent ... Court for the District of Delaware ... covering technology related to stimulation leads, batteries, and telemetry ...
(Date:12/9/2016)... MSD, a nationally recognized supplier of technology ... site health care facilities, announced today that it has ... Choice"), a privately held national distributor of medical supplies ... health segments. We would like to welcome First Choice ... transaction will deliver significant and immediate value to MSD,s ...
(Date:12/9/2016)... , December 9, 2016 ... ICD, Single-Chamber ICD, Dual-Chamber ICD, Cardiac Resynchronization Therapy ... Wearable Cardioverter Defibrillators The global ... a CAGR of 5.3% from 2016-2020 and CAGR ... to grow at a CAGR of 5.2% from ...
Breaking Medicine Technology: